glucagon has been researched along with Dyslipidemia in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrés, A; de Solís, AJ; Fernández, A; Gallardo, N; López, V; Mazuecos, L; Pintado, C; Rodríguez, M; Rubio, B | 1 |
| Baba, K; Piccione, G; Tchio, C; Tosini, G | 1 |
| Aguilera-Aguilera, R; Gonzalez-Cara, C; Mendoza, FJ; Perez-Ecija, A; Toribio, RE | 1 |
| Clemmensen, C; DiMarchi, RD; Finan, B; Hofmann, SM; Jall, S; Müller, TD; Neff, F; Sachs, S; Tschöp, MH | 1 |
| Bahekar, R; Jain, M; Joharapurkar, A; Kshirsagar, S; Pandey, D; Patel, D; Patel, H; Patel, M; Patel, V; Sutariya, B | 1 |
| Bahekar, R; Jain, M; Joharapurkar, A; Kadam, S; Kshirsagar, S; Pandey, D; Patel, D; Patel, H; Patel, M; Patel, V; Ranvir, R; Sutariya, B | 1 |
| Cardoso, CG; da Costa Aguiar Alves Reis, B; de Marco Ornelas, E; Fonseca, FLA; Lima, NEA; Maifrino, LBM; Marques, MR; Veloso, AGB | 1 |
| Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D | 1 |
| Bhasin, S; Castellani, LW; Guo, W; Hamilton, JA; Herbst, KL; Hruz, PW; Hua, N; Tu, P | 1 |
| Adeli, K; Baker, C; Bradshaw, CD; Brant, AF; Cramer, CT; Filippov, S; Hanselman, JC; Houghton, JL; Hurley, TR; Naples, M; Newton, RS; Pinkosky, SL; Spahr, MA; Srivastava, RA | 1 |
1 trial(s) available for glucagon and Dyslipidemia
| Article | Year |
|---|---|
Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients.
Topics: Adult; Anthropometry; Berberis; Bicycling; Blood Glucose; Combined Modality Therapy; Diet, Reducing; Dietary Supplements; Double-Blind Method; Drug Combinations; Dyslipidemias; Exercise Therapy; Female; Glucagon; Humans; Hypolipidemic Agents; Insulin; Insulin Secretion; Lipids; Lipoproteins; Male; Middle Aged; Overweight; Phytotherapy; Plant Preparations; Silybum marianum | 2013 |
9 other study(ies) available for glucagon and Dyslipidemia
| Article | Year |
|---|---|
Effects of Moderate Chronic Food Restriction on the Development of Postprandial Dyslipidemia with Ageing.
Topics: Adiposity; Aging; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Blood Glucose; Diet, Fat-Restricted; Dietary Fats; Disease Models, Animal; Dyslipidemias; Glucagon; Insulin; Lipids; Liver; Metabolic Syndrome; Postprandial Period; Rats; Rats, Wistar; Triglycerides | 2019 |
Removal of melatonin receptor type 1 signalling induces dyslipidaemia and hormonal changes in mice subjected to environmental circadian disruption.
Topics: Animals; Chronobiology Disorders; Dyslipidemias; Female; Ghrelin; Glucagon; Insulin; Leptin; Lipid Metabolism; Male; Mice, Knockout; Receptor, Melatonin, MT1; Resistin; Signal Transduction | 2021 |
Energy hormone response to fasting-induced dyslipidemia in obese and non-obese donkeys.
Topics: Adiponectin; Animals; Blood Glucose; Dyslipidemias; Energy Metabolism; Equidae; Fasting; Female; Ghrelin; Glucagon; Insulin; Insulin-Like Growth Factor I; Leptin; Lipids; Obesity | 2021 |
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.
Topics: Adiposity; Animals; Diet, High-Fat; Dyslipidemias; Eating; Fatty Liver; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Male; Mice; Mice, Inbred C57BL; Obesity; Sex Factors | 2017 |
Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia.
Topics: Animals; Cholesterol; Dyslipidemias; Energy Metabolism; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Homeostasis; Lipid Metabolism; Liver; Male; Mesocricetus; Obesity; Receptors, Glucagon; Signal Transduction; Triglycerides | 2018 |
Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition.
Topics: Animals; Atherosclerosis; Cholesterol; Cricetinae; Dyslipidemias; Glucagon; Glucagon-Like Peptide 1; Inflammation; Lipid Metabolism; Liver; Male; Mice; Mice, Transgenic; Receptors, Glucagon | 2018 |
Effects of moderate exercise on biochemical, morphological, and physiological parameters of the pancreas of female mice with estrogen deprivation and dyslipidemia.
Topics: Animals; Dyslipidemias; Estrogens; Female; Glucagon; Insulin; Intra-Abdominal Fat; Menopause; Mice, Inbred C57BL; Mice, Knockout; Ovariectomy; Pancreas; Physical Conditioning, Animal; Receptors, LDL | 2018 |
Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice.
Topics: Adipose Tissue; Animals; Atherosclerosis; Blood Glucose; Body Composition; Dyslipidemias; Gene Deletion; Glucagon; Insulin; Lipids; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Myostatin; Receptors, LDL | 2009 |
AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; ATP Citrate (pro-S)-Lyase; Biomarkers; Calcium; Carbohydrate Metabolism; Cricetinae; Dicarboxylic Acids; Diet; Dyslipidemias; Energy Metabolism; Enzyme Activation; Enzyme Inhibitors; Fatty Acids; Female; Glucagon; Glucose; Hep G2 Cells; Humans; Lipid Metabolism; Liver; Male; Mice; Molecular Targeted Therapy; Obesity; Protein Serine-Threonine Kinases; Rats; Signal Transduction; Sterols | 2013 |